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Introduction: We report the cases of three patients with advanced
non-small cell lung cancer responding to erlotinib after progression
under gefitinib treatment.
Methods: Three never-smoker women with advanced lung adeno-
carcinoma, two pretreated with chemotherapy and with gefitinib and
one with gefitinib alone, received erlotinib in a daily dose of 150 mg.
All three patients had disease progression and had achieved tumor
control with gefitinib.
Results: The first patient achieved partial response of lung lesions,
the second had partial response of brain lesions and stable disease of
lung and bone disease, and the third had partial response of brain
lesions and stable disease of lung disease. At the time of this
analysis, all three patients were still receiving treatment with erlo-
tinib with no evidence of treatment failure after more than 13, 13,
and 7 months, respectively. Erlotinib was generally well tolerated,
with grade 1 skin toxicity recorded in two patients.
Conclusions: Erlotinib may be effective in patients with non-small
cell lung cancer who were previously and successfully treated with
gefitinib. However, careful selection of these patients is needed.
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The epidermal growth factor receptor (EGFR) is a trans-membrane receptor found primarily on cells of epithelial
origin. Autophosphorilation of its intracellular domain ini-
tiates a cascade of events leading to cell proliferation. EGFR
is commonly expressed at a high level in a variety of solid
tumors, and it has been implicated in the control of cell
survival, proliferation, metastasis, and angiogenesis.1 Ge-
fitinib and erlotinib are two orally available EGFR tyrosine
kinase inhibitors (EGFR-TKIs). Two large phase II trials of
gefitinib monotherapy have been conducted among patients
with advanced non-small cell lung cancer (NSCLC) that
progressed after one or more chemotherapy regimens. In
these two studies, named IDEAL 1 and 2 (Iressa Dose
Evaluation in Advanced Lung cancer), gefitinib was demon-
strated to be active and well tolerated.2,3 However, very
recently, Thatcher et al. reported a phase III trial (ISEL)
comparing gefitinib with best supportive care among patients
with advanced NSCLC who had received one or two prior
chemotherapy regimens.4 In 1692 patients, a difference be-
tween gefitinib and placebo was reported, although this did
not reach a statistical significance in the overall population
(5.6 vs 5.1 months; HR, 0.89; 95% CI, 0.78–1.03; p  0.11).
Pre-planned subgroup analyses suggested survival benefits
for gefitinib and placebo among patients of Asian origin and
patients who never smoked, respectively. In a phase III,
randomized, placebo-controlled trial, erlotinib prolonged sur-
vival (6.7 vs 4.7 months for erlotinib vs placebo; p  0.001)
among patients with NSCLC after first- or second-line che-
motherapy.5 The analysis of quality of life and time to
deterioration of patients reported symptoms showed statisti-
cally and clinically meaningful benefit for patients random-
ized to erlotinib.6 Tsao et al. used tumor biopsy samples from
participants in the afore-mentioned trial to investigate
whether responsiveness to erlotinib and its impact on survival
were associated with expression by the tumor of EGFR and
EGFR gene amplification and mutations.7 In multivariate
analyses adenocarcinoma (p  0.01), never having smoked
(p  0.01) and expression of EGFR (p  0.03) were asso-
ciated with an objective response.
Somatic mutations in the EGFR have been identified
among patients with advanced NSCLC who achieve dramatic
clinical and radiographic response to the EGFR-TKIs ge-
fitinib and erlotinib.8,9 These mutations in EGFR are found
more frequently in patients with adenocarcinomas, never-
smokers, patients of Asian ethnicity, and women—the same
populations that are most likely to have a clinical response
when treated with EGFR-TKIs. Retrospective studies compar-
ing the outcomes of patients with and without EGFR mutations
treated with EGFR-TKIs show a significant clinical benefit of
EGFR-TKIs among patients with EGFR mutations.10
*Division of Medical Oncology, S.G. Moscati Hospital, Avellino; †Medical
Oncology Department, Oncology Institute, Bari, Italy.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Dr. Cesare Gridelli, Division of Medical On-
cology, S.G. Moscati Hospital, Contrada Amoretta, 83100 Avellino,
Italy. E-mail: cgridelli@libero.it
Copyright © 2007 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/07/0208-0758
Journal of Thoracic Oncology • Volume 2, Number 8, August 2007758
Comparative data between erlotinib and gefitinib or
evidences on cross-resistance do not exist, as it is unknown
whether some patients who do not respond to erlotinib can
benefit from gefitinib and vice versa. In this article, we report
three cases of long-lasting tumor control with erlotinib after
disease progression during gefitinib therapy in advanced
NSCLC.
PATIENTS AND METHODS
All three patients received erlotinib once daily at the
dose of 150 mg. Patient characteristics are summarized in
Table 1. Patients were women aged 67, 38, and 50 years. All
three patients were never-smoker whose histology was ade-
nocarcinoma. Two patients received chemotherapy before
gefitinib (one pretreated with cisplatin plus vinorelbine and
then by gemcitabine, and one with cisplatin plus gemcitabine
and then by carboplatin plus paclitaxel). One patient never
received chemotherapy because of liver cirrhosis. Two pa-
tients had brain metastasis. All three patients received ge-
fitinib just before therapy with erlotinib: two reported stable
disease and one partial response. During gefitinib therapy, the
first patient progressed on lung, whereas the second and third
progressed on lung and brain. In particular, new lesions
appeared in all three cases. Only fine-needle ago-biopsies
with cytological examinations were available for these three
patients. Thus, mutational analysis was not performed.
RESULTS
At the time of this analysis, all the three patients are
still on treatment with erlotinib with no evidence of treatment
failure after more than 13, 13, and 7 months. Patient 1
achieved partial response, and Patients 2 and 3 achieved
stable disease. Specifically, Patient 1 achieved partial re-
sponse on lung lesions (Figure 1), Patient 2 achieved partial
response on brain lesions (Figure 2) and stable disease on
lung and bone lesions, and Patient 3 achieved partial response
on brain lesions and stable disease on lung lesions. All three
patients experienced symptomatic improvement in cerebral
and extracerebral symptoms while receiving treatment. Erlo-
tinib was generally well tolerated, with grade 1 skin toxicity
recorded in two cases.
DISCUSSION
In our series, we found three cases of long-lasting
tumor control with erlotinib after disease progression with
gefitinib in the treatment of advanced NSCLC. One patient
achieved partial response, and two patients achieved stable
disease. All three patients had adenocarcinomas, were women
and never-smokers, and had previously achieved tumor con-
trol with gefitinib. Thus, we described clinical cases of
patients selected by clinical predictive factors of response.
Garfeld recently reported the case of an elderly patient,
male and former smoker, with advanced NSCLC (cell type
not specified) that responded to erlotinib after an immediate
failure to gefitinib therapy.11 This case is very interesting but
different from our cases because gefitinib did not achieve
tumor control as in our cases and because the patient de-
scribed by Garfeld represents the NSCLC patient population
with lower response rates to EGFR inhibitors (male, non-
adenocarcinoma, and former smoker). On the contrary,
Choong et al. recently described the case of a 70-year-old
Japanese-American woman who had never smoked with
advanced NSCLC.12 Whereas during treatment with erlo-
tinib she progressed, developing leptomeningeal carcino-
matosis, and she achieved tumor response to gefitinib. The
authors also performed a mutational analysis and found in
this tumor a novel double L858R  E884K somatic
mutation of the EGFR.
Differential activity between gefitinib and erlotinib is
unknown. Somatic mutations in the EGFR have been de-
tected among patients with NSCLC (especially those with
adenocarcinoma and never-smokers) and are associated with
sensitivity to treatment with gefitinib or erlotinib, but the
relationship between different mutations and the activity of
TABLE 1. Patient Characteristics, Response, and Toxicity
Case 1 Case 2 Case 3
Age 67 38 50
Sex Female Female Female
Prior smoking history Never smoker Never smoker Never smoker
Histology Adenocarcinoma Adenocarcinoma Adenocarcinoma
EGFR status Unknown Unknown Unknown
Stage IV IV IV
Disease sites Lung Lung, bone, brain Lung, brain
Number of previous chemotherapies 0 2 2
Response to gefitinib Stable disease for 18 months Stable disease for 12 months Stable disease for 24 months
Progression status of gefitinib New lung lesions New lung and brain lesions New lung and brain lesions
Response to erlotinib Partial response Stable disease Stable disease
Brain Partial response Partial response
Extracranial disease Partial response (lung) Stable disease (lung and bone) Stable disease (lung)
Duration of response 13 13 7
Toxicity
Site (grade) Skin (1) Skin (1)
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the two EGFR-TKIs has not yet been deeply studied. Some
common somatic mutations in EGFR, including deletion
mutations in exon 19 and leucine-to-arginine substitution at
amino acid position 858 (L858R) in exon 21, have been
examined for their ability to predict sensitivity to gefitinib or
erlotinib.8,9 However, reports have shown that the threonine-
to-methionine substitution at amino acid position 790
(T790M) in exon 20 is related to gefitinib resistance.13 Some
studies have indicated that high copy numbers of the EGFR
gene may be a more effective molecular predictor to respon-
siveness and prolonged survival among patients treated with
EGFR-TKIs.14 Tokumo et al. recently described two patients
with NSCLC with the L858R mutation who did not respond
to gefitinib.15 Patient 1 harbored both the T790M and L858R
mutations, and fluorescence in situ hybridization showed
EGFR gene amplification. Patient 2 harbored both the L858R
and aspartic acid-to-tyrosine substitution at amino acid posi-
tion 761 in exon 19 of EGFR mutations and had a high
polysomy status for EGFR. In these two patients, tumors
showed resistance to gefitinib treatment despite the presence
of EGFR L858R mutation and increased copy number. Jack-
man et al. recently explored the relationship between the two
most common types of somatic EGFR mutations, exon 19
deletions and the L858R point mutation, and outcomes of
patients after treatment with gefitinib or erlotinib.16 In 36
patients, those with an exon 19 deletion had a significantly
FIGURE 1. Patient 1 achieved par-
tial response on lung lesions after
erlotinib therapy (left, baseline).
FIGURE 2. Patient 2 achieved par-
tial response on brain lesions after
erlotinib therapy (left, baseline).
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longer overall survival compared with patients with an
L858R mutation (38 vs 17 months; p  0.04), and a trend
toward higher response rate (73% vs 50%). Interestingly, we
also noted a difference in response rate for patients treated
with gefitinib compared with erlotinib (18 of 23 [78%] vs 3
of 9 [33%]; p  0.04]. However, the number of patients
available in this analysis is not sufficient for definitive con-
clusions on differential activity between gefitinib and erlo-
tinib. Pooling of greater numbers of patients and completion
of prospective trials are needed to further define the predic-
tive and prognostic roles of different EGFR mutations with
respect to treatment with gefitinib, erlotinib, and other EGFR
inhibitors.
In conclusion, our three cases demonstrate that erlotinib
may be effective among patients with NSCLC previously and
successfully treated with gefitinib. However, a careful selec-
tion of these patients is needed, and candidates for this switch
are only to be found among never-smokers. The search for
patients who do not respond to erlotinib but who respond to
gefitinib or vice versa would also be useful for clinical
practice. Only a detailed correlation between molecular anal-
ysis of somatic mutations of EGFR and clinical outcomes of
the two EGFR-TKIs may clarify how to select patients with
NSCLC with gefitinib-resistant and erlotinib-sensitive dis-
ease and vice versa.
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